The Global Sepsis Diagnostics market is valued around USD 934.54 million in 2018 and predicted to be developing at a CAGR of 8.51%, to reach USD 1405.88 million by 2023. Sepsis is a life threatening condition because of the response of host immune system to a bacterial contamination. It causes injury to its own tissues and organs. Sepsis is taken into consideration as a three-staged syndrome by physicians that start with sepsis, leading to intense sepsis, and eventually septic shock. Excessive sepsis is related to organ dysfunction and acute alteration in mental status.
Factors affecting market growth:
- Increase in the number of product approvals (+)
- High incidence of hospital acquired infection (+)
- Rise in demand for antibiotic resistant bacteria strain (+)
- Growing number of surgical procedures (+)
- Escalating aging population (+)
- Shortage of skilled professionals (-)
- Lack of standard protocols (-)
Get your customized report:https://www.marketdataforecast.com/market-reports/sepsis-diagnostics-market-2943/customize-report
The Global Sepsis Diagnostics market is geographically segmented into
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
North America is leading the market even as Europe is at the 2nd vicinity. Increasing awareness of stakeholders on research tasks, drug discovery and diagnosis has helped North America to dominate the market.
Browse full Table of Contents: https://www.marketdataforecast.com/market-reports/sepsis-diagnostics-market-2943/
Some of the prominent industries dominating this market include bioMérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.
Company Name: Market Data Forecast
Contact Person: Abhishek Shukla
Email: Send Email
Address:2nd Floor, Lakeview Plaza, Kavuri Hills, flimnagar